Anika reported third-quarter revenue of $30.6 million, up 10%, and gross margin of 62%, raising 2026 revenue growth guidance to 6% to 10%. HylaFast’s PMA was deemed not approvable, while Integrity revenue grew more than 30% year over year.
ANIK · Anika Therapeutics, Inc. · Documents
One customer — 49% of revenue (nine-months ended September 30, 2026)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 47% of revenue (three-months ended September 30, 2026)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 51% of revenue (three-months ended September 30, 2025)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 50% of revenue (nine-months ended September 30, 2025)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Anika Therapeutics reported revenue of 30,594 thousand U.S. dollars and a net loss of 311 thousand U.S. dollars for the three months ended September 30, 2026.
Anika Therapeutics reported third-quarter revenue of $30.6 million, up 10% year over year, raised 2026 revenue guidance to 6% to 10% and adjusted EBITDA margin guidance to 15% to 17%, while receiving FDA notice that Hyalofast PMA application was not approvable.